Chemoinformaics analysis of  Cycloprotobuxine-D
| Molecular Weight | 386.668 | nRot | 3 |
| Heavy Atom Molecular Weight | 340.3 | nRig | 22 |
| Exact Molecular Weight | 386.366 | nRing | 5 |
| Solubility: LogS | -4.161 | nHRing | 0 |
| Solubility: LogP | 4.836 | No. of Aliphatic Rings | 5 |
| Acid Count | 0 | No. of Aromatic Rings | 0 |
| Base Count | 2 | No. of Aliphatic Carbocycles Rings | 5 |
| Atoms Count | 74 | No. of Aliphatic Hetero Cycles | 0 |
| No. of Heavy Atom | 28 | No. of Aromatic Carbocycles | 0 |
| nHetero | 2 | No. of Aromatic Hetero Cycles | 0 |
| nBridge Head | 0 | No. Saturated Carbocycles | 5 |
| No. of Hydrogen atom | 46 | No. of Saturated Hetero Cycles | 0 |
| No. of Carbon atom | 26 | No. of Saturated Rings | 5 |
| No. of Nitrogen atom | 2 | No. of Arom Atom | 0 |
| No. of Oxygen atom | 0 | No. of Arom Bond | 0 |
| nHA | 2 | APOL | 76.2925 |
| nHD | 2 | BPOL | 47.2875 |
| QED | 0.657 |
| Synth | 5.58 |
| Natural Product Likeliness | 2.979 |
| NR-PPAR-gamma | 0.005 |
| Lipinski | Accepted |
| Pfizer | Rejected |
| GSK | Rejected |
| Golden Triangle | Accepted |
| Pgp-inh | 0.025 |
| Pgp-sub | 0 |
| HIA | 0.2 |
| CACO-2 | -5.294 |
| MDCK | 0.00000879 |
| BBB | 0.196 |
| PPB | 0.705997 |
| VDSS | 0.892 |
| FU | 0.225684 |
| CYP1A2-inh | 0.013 |
| CYP1A2-sub | 0.419 |
| CYP2c19-inh | 0.051 |
| CYP2c19-sub | 0.967 |
| CYP2c9-inh | 0.065 |
| CYP2c9-sub | 0.096 |
| CYP2d6-inh | 0.651 |
| CYP2d6-sub | 0.919 |
| CYP3a4-inh | 0.599 |
| CYP3a4-sub | 0.806 |
| CL | 10.717 |
| T12 | 0.018 |
| hERG | 0.11 |
| Ames | 0.009 |
| ROA | 0.259 |
| SkinSen | 0.227 |
| Carcinogencity | 0.019 |
| EI | 0.004 |
| Respiratory | 0.962 |
| NR-Aromatase | 0.003 |
| Antiviral | No |
| Prediction | 0.763687 |